Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats
Md. Akbar , Hasan Ali , Md. Azizur Rahman
Intelligent Pharmacy ›› 2024, Vol. 2 ›› Issue (2) : 226 -231.
Comparative evaluation of carvedilol and pitavastatin for antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats
Aim of the study was designed to investigate the antihyperlipidemic activity of carvedilol and pitavastatin in tyloxapol-induced hyperlipidemia in Wistar rats. The rats were randomly divided into 6 groups. The vehicle control group-I received 2 mL of normal saline for eight days. The pathological control group-II received tyloxapol (400 mg/kg) on 8th day. The treated group-III received 10 mg/kg carvedilol and group-IV received 20 mg/kg carvedilol for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-V received pitavastatin (0.3 mg/ kg) for eight days and tyloxapol (400 mg/kg) on the 8th day. The group-VI received carvedilol (20 mg/kg) only for eight days. After eight days of treatment, triglycerides, total cholesterol, high-density lipoprotein, very lowdensity lipoprotein, thiobarbituric acid reactive substances, and glutathione were estimated in the serum and myocardial tissues along with DNA fragmentation of the liver tissue using gel-electrophoresis. Oral administration of carvedilol to tyloxapol-induced hyperlipidemic rats normalized the changes in the above parameters in a dose dependent manner. Hence, carvedilol with pitavastatin has antihyperlipidemic activity in tyloxapol-induced hyperlipidemia in Wistar rats.
Carvedilol / Pitavastatin / Triton WR-1339 / Tyloxapol / DNA damage / Oxidative stress
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
/
| 〈 |
|
〉 |